Finding Aggressive Prostate Cancer Early
Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches
This research aims to find better ways to identify aggressive prostate cancer right when it's diagnosed, helping doctors choose the best treatments for men.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11137694 on NIH RePORTER |
What this research studies
Many men with prostate cancer receive treatment, but some still experience their cancer returning because it was more aggressive than initially thought. Current imaging methods have limitations in clearly showing the true nature of the cancer. This project uses a special type of MRI, called diffusion basis spectral imaging (DBSI), which can see detailed changes in the prostate that regular MRI might miss. Researchers are also looking at specific markers in the body, called proteoglycomic biomarkers, that are linked to more dangerous forms of prostate cancer. By combining these advanced imaging and biomarker discoveries, the goal is to improve how we detect and understand aggressive prostate cancer from the start.
Who could benefit from this research
Good fit: This research is relevant for men diagnosed with prostate cancer, particularly those whose disease might be aggressive or at risk of recurrence.
Not a fit: Patients without a prostate cancer diagnosis or those with very early, non-aggressive forms of the disease may not directly benefit from this specific diagnostic improvement.
Why it matters
Potential benefit: If successful, this work could lead to more accurate diagnoses for prostate cancer, allowing doctors to tailor treatments more effectively and potentially improve survival rates for patients.
How similar studies have performed: The advanced MRI technique (DBSI) is noted as a significant advancement, and the research team has already discovered relevant proteoglycomic biomarkers, suggesting a foundation of prior work and novel findings.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ippolito, Joseph Edward — Washington University
- Study coordinator: Ippolito, Joseph Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.